Table 3 Comparison of baseline and follow-up metabolic parameters.
Baseline | Follow-up | Follow-up | |
|---|---|---|---|
(n = 90) | (all subjects, n = 90) | (antipsychotic-treated subjects, n = 83) | |
BMI, kg/m2 | 29.2 (5.1) | 29.9 (4.9)* | 29.8 (4.9)* |
BMI category | |||
Underweight (%) | 1.1 | 2.2 | 2.4 |
Normal (%) | 16.7 | 10.0 | 8.4 |
Overweight (%) | 34.4 | 43.3* | 44.6* |
Obese (%) | 47.8 | 44.4 | 44.6 |
Waist Circumference, cm | 94.6 (13.2) | 96.2 (13.1) † | 96.2 (13.0) † |
Fasting blood glucose, mmol/l | 5.6 (2.4) | 5.5 (1.4) | 5.5 (1.4) |
HbA 1c, % | 5.4 (1.2) | 5.6 (1.0) | 5.6 (1.0) |
Serum insulin, MU/l | 12.9 (13.4) | 11.1 (8.1) | 11.1 (8.2) |
HOMA B, % | 106.3 (38.6) | 98.8 (38.8) † | 99.7 (39.7) |
HOMA S, % | 95.9 (60.5) | 98.6 (55.6) | 98.4 (55.6) |
HOMA IR, % | 1.8 (1.7) | 1.5 (1.1) † | 1.5 (1.1) |
Glycaemic status | |||
Normoglycaemia, % | 86.7 | 85.6 | 86.8 |
Impaired fasting glucose, % | 6.7 | 8.9 | 7.2 |
Diabetes Mellitus, % | 6.7 | 5.6 | 6.0 |
Total Cholesterol, mmol/l | 5.6 (1.2) | 5.7 (1.5) | 5.7 (1.5) |
Raised total cholesterol, % | 27.8 | 28.9 | 31.3 |
HDL-Cholesterol, mmol/l | 1.3 (0.4) | 1.3 (0.4) | 1.3 (0.4) |
LDL-Cholesterol, mmol/l | 3.2 (0.9) | 3.3 (1.1) | 3.3 (1.3) |
Triglycerides, mean (range), mmol/l | 2.3 (0.6–8.4) | 2.1 (0.5–6.9) | 2.1 (0.5–6.9) |
Raised total triglycerides, % | 53.3 | 51.1 | 53.0 |
Lipid-lowering therapy, % | 4.4 | 7.8 | 7.2 |